Imigran (Sumatriptan)

Sumatriptan selectively activates 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and sensory nerves, causing vasoconstriction and blocking the release of inflammatory neuropeptides, thereby interrupting the migraine cascade.

The appropriate dose of Imigran is determined by a qualified prescriber based on the individual’s clinical condition, age, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety of sumatriptan during pregnancy or lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Imigran.

To request Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Imigran (sumatriptan) belongs to the triptan class, which provides rapid migraine relief through serotonin receptor agonism. Compared with non‑specific analgesics, triptans target the underlying vascular and neurogenic mechanisms, often resulting in faster and more complete headache resolution.

Imigran should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, excessive heat, and direct sunlight to maintain product stability.

Imigran is taken orally, usually as a tablet, and should be swallowed with water. The medication is intended for use at the onset of migraine symptoms, and patients should follow the dosing instructions given by their healthcare provider.

Serious risks include chest pain or tightness that may indicate cardiac ischemia, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic drugs. Any of these symptoms require immediate medical attention.

Imigran is contraindicated in individuals with known coronary artery disease, uncontrolled hypertension, a history of stroke or transient ischemic attack, severe hepatic impairment, or in patients currently taking MAO inhibitors or ergot derivatives.